Markets

Insider Trading

Hedge Funds

Retirement

Opinion

15 Most Depressed States in the US

In this article, we will be taking a look at the 15 most depressed states in the US. If you are not interested in learning about the global and regional trends in the depression treatment market, head straight to the 5 Most Depressed States in the US

Global and Regional Trends in the Depression Treatment Market 

The global depression treatment market is expected to reach USD 16.14 billion by 2030, growing from USD 11.31 billion in 2022 at a CAGR of 4.6% during the forecast period. The North American region which is led by the U.S., emerged as the most significant market, accounting for a 44.11% share of global revenue in 2022. Around 29% of Americans in 2023 were diagnosed with depression in their lifetime and 17.8% of the people were currently fighting depression. This was the highest ever rate recorded since 2015. The 2023 CDC data showed that the age-standardized depression prevalence ranged from 12.7% in Hawaii to 27.5% in West Virginia, with a median of 19.9% in the US.

Globally, depression is a major contributor to disability, with the World Health Organization estimating that over 280 million people worldwide have depression. Depression is most common in the 45-64 age group, affecting 40% of those with depression in the U.S.

If we talk about Asia, The Depressive Disorders market in Asia is forecasted to grow by 1.36% from 2024 to 2028, reaching €5.90 billion in 2028. In Southeast Asia, the market is expected to grow by 0.89% during the same period, with a market volume of US$0.86 billion in 2028.

Drugs dominate the depression treatment market globally, comprising over 99.4% of the demand share in 2021. ECT (Electroconvulsive Therapy) market is one of the fastest-growing depression treatments when it comes to treating depression which is set to double by 2030, propelled by up to 90% response rate in MDD cases. Antidepressant usage has also risen in the US, with 13.2% of adults, especially women, reported as users. Leading medications like Sertraline, Trazodone, Fluoxetine, and Bupropion treat various conditions beyond depression, including OCD, social anxiety, panic disorder, GAD, and PTSD, targeting brain neurotransmitter activity.

Recent surveys by the U.S. Census Bureau reveal higher rates of depression among young adults in the LGBT community. Additionally, the increasing reliance on antidepressants in the U.S. is evident, with Sertraline (Zoloft) being the most prescribed psychiatric medication in 2020.

Leading Innovations in Depression Treatment

If we talk about health companies that are actively working to treat depression, include Biogen Inc. (NASDAQ:BIIB), Sage Therapeutics, Inc. (NASDAQ:SAGE), and Axsome Therapeutics, Inc. (NASDAQ:AXSM) among others. Biogen Inc. (NASDAQ:BIIB)’s most significant contribution to the depression treatment landscape is zuranolone, a once-daily, 14-day investigational drug that was developed in partnership with Sage Therapeutics. Financially, Biogen’s total revenue declined 7% year-over-year to $2.3 billion in Q1 2024 which was driven by a 3% drop in product revenue and significant reductions in contract manufacturing and other revenues. Biogen Inc. (NASDAQ:BIIB)’s revenue from anti-CD20 therapeutics and other product lines declined, partially offset by a 2% increase in biosimilar revenue. Biogen Inc. (NASDAQ:BIIB) also launched new products like Leqembi for Alzheimer’s during the same time frame.

Sage Therapeutics, Inc. (NASDAQ:SAGE) is one of the biggest biopharmaceutical companies. The company has made significant strides in the field of depression treatment with the development of ZURZUVAE (zuranolone) which is a rapid-acting oral medication approved by the FDA for postpartum depression (PPD). In addition to ZURZUVAE, Sage Therapeutics, Inc. (NASDAQ:SAGE) has another promising candidate, zuranolone (SAGE-217) which is currently in development for major depressive disorder (MDD). Their dalzanemdor (SAGE-718) is also being investigated for cognitive impairment in Huntington’s disease, Alzheimer’s disease, and mild dementia. Financially, in Q1 2024, Sage Therapeutics, Inc. (NASDAQ:SAGE) reported total revenue of $7.9 million, exceeding estimates of $5.66 million which was driven by $6.2 million in collaboration revenue from ZURZUVAE. Their research & development expenses decreased 23% year-over-year to $71.7 million during the same period.

Last but not least, Axsome Therapeutics, Inc. (NASDAQ:AXSM) has also been contributing to treating depression. Axsome’s major contribution is AUVELITY (dextromethorphan-bupropion) which is an oral medication approved by the FDA in 2022 for the treatment of major depressive disorder in adults. In addition to AUVELITY, Axsome has a robust pipeline of investigational therapies targeting various CNS disorders.  Financially, Axsome Therapeutics, Inc. (NASDAQ:AXSM) reported a total net product revenue of $75.0 million for Q1 2024. Their Auvelity’s net product sales reached $51.5 million in Q1 2024, while Sunosi ‘s net product revenue reached $23.5 million in Q1 2024, a 17% increase over Q1 2023.

Pixabay/Public Domain

Our Methodology 

For our methodology, we have ranked the most depressed states in the US based on depression rates per 100,000 people in these states as of 2022. Since the data was available for the overall depression prevalence rate in these states, we did some calculations to fin out the rates per 100,000 population. Firstly, We multiplied depression rates for each state with their total populations and then the resulting answer was divided by the total population again. The result was further multiplied by 100,000 to get per 100,000 rates.

Here is our list of the 15 most depressed states in the US. 

15. Oregon 

Depression Rate per 100,000 People: 24,000 

Oregon stands among the US states that have the most seasonal depression. The depression rate per 100,000 people stands at 24,000. In 2023, 12.7% of Oregon youth aged 12–17 experienced a major depressive episode, according to the National Survey on Drug Use and Health. In terms of treatment, Oregon has a limited number of resources for depression, particularly for severe cases. The state has only 40 beds for the most acute cases of youth mental illness, and many areas lack access to psychiatrists and other mental health professionals.

14. Alabama 

Depression Rate per 100,000 People: 24,008 

Alabama stands among the most depressed states in the US with a depression prevalence rate of 24,008 per 100,000 people. The Substance Abuse and Mental Health Services Administration (SAMHSA) estimates that in 2014-2015, an annual average of about 148,000 adults aged 18 or older (4.0% of all adults) in Alabama had serious thoughts of suicide. Additionally, an annual average of about 42,000 adolescents aged 12-17 (11.0% of all adolescents) in Alabama experienced a major depressive episode in 2014-2015. According to a national study analyzing data from 2008-2016, among those with depression in the United States, 40% were aged 45-64 years, and 61% were female.

13. Montana 

Depression Rate per 100,000 People: 24,490 

The depression prevalence rate in Montana is 24,490 per 100,000 people. The 2018 BRFSS data showed that among Montana adults who reported ever being diagnosed with depression and experiencing frequent mental distress were 56.2% female, compared to 43.8% male. The highest depression prevalence was among those aged 35-44 years (14.7%), followed by those aged 45-54 years (13.4%).

12. Vermont 

Depression Rate per 100,000 People: 24,804 

Vermont has one of the highest depression rates in the US with around 24,804 per 100,000 people being depressed. Lower income levels and poverty are the two most common reasons for depression in the state with a 2021 report highlighting that 33% of low-income Vermont adults reported poor mental health. In 2021, 26% of adults aged 18-44 reported poor mental health. LGBTQ+ adults in Vermont had a 31% rate of poor mental health in 2021 while adults with disabilities reported a 33% rate of poor mental health in the same year. Vermont is one of the most saddest states in the US.

11. Washington 

Depression Rate per 100,000 People: 25,000 

Around 25,000 per 100,000 people are depressed in Washington. Around 22% of youth in Washington seriously considered suicide in 2021, up 6% since 2011.

10. Ohio 

Depression Rate per 100,000 People: 25,000 

Ohio stands among the top 10 depressed states in the US with a depression rate of 25,000 per 100,000 people. The prevalence of depression in Ohio is higher than the national average, with one in four adults (25%) in Franklin County having been diagnosed with depression. The opioid epidemic and its impacts have also played a significant role in the state’s mental health crisis and rising depression cases.

9. New Hampshire 

Depression Rate per 100,000 People: 25,290 

New Hampshire is one of the most depressed states in America92,510 people in New Hampshire lack access to sufficient mental health professionals in their communities.

8. Kentucky 

Depression Rate per 100,000 People: 25,830 

Kentucky is one of the top 10 depressed states in the US. The prevalence of depression and anxiety disorders (DAD) among Kentucky Medicaid patients increased from 30.8% in 2012 to 36.3% in 2019, according to a study based on Kentucky Medicaid. This translates to over 325,000 cases of DAD among Kentucky Medicaid patients in 2019. The study found that the utilization of pharmacologic treatment (medication) for DAD among Kentucky Medicaid patients increased from 62.9% in 2012 to 67.3% in 2019. However, the utilization of psychosocial therapies (counseling, psychotherapy) remained low, increasing only slightly from 10.9% in 2012 to 13.7% in 2019.

7. Maine 

Depression Rate per 100,000 People: 26,311 

The depression rate in Maine is 26,311 per 100,000 people. In 2019, nearly 1 in 3 high school students in Maine felt sad or hopeless almost every day for two weeks or more. Talking about Maine, the Lewiston city in the state is one of the five cities in the US with the highest depression rates. In 2018, about 1 in 10 Maine women with a recent birth suffered from postpartum depression, with higher rates among those with lower incomes and education levels.

6. Louisiana 

Depression Rate per 100,000 People: 26,402 

Louisiana stands sixth among the most depressed states in the US with a depression prevalence rate of 26,402 per 100,000 people. With a total population of around 4.6 million people in Louisiana as of 2022, this translates to over 1 million adults potentially experiencing depression. Younger adults, particularly those aged 18-24 years, tend to have higher rates of depression compared to older age groups. From 2019 to 2021, the percentage of Louisiana citizens reporting a history of depression increased from 23.9% to 26.4%.

Click to see and continue reading the 5 Most Depressed States in the US.

Suggested Articles:

Disclosure. None: The 15 Most Depressed States in the US is originally published on Insider Monkey.

AI Fire Sale: Insider Monkey’s #1 AI Stock Pick Is On A Steep Discount

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!

The whispers are turning into roars.

Artificial intelligence isn’t science fiction anymore.

It’s the revolution reshaping every industry on the planet.

From driverless cars to medical breakthroughs, AI is on the cusp of a global explosion, and savvy investors stand to reap the rewards.

Here’s why this is the prime moment to jump on the AI bandwagon:

Exponential Growth on the Horizon: Forget linear growth – AI is poised for a hockey stick trajectory.

Imagine every sector, from healthcare to finance, infused with superhuman intelligence.

We’re talking disease prediction, hyper-personalized marketing, and automated logistics that streamline everything.

This isn’t a maybe – it’s an inevitability.

Early investors will be the ones positioned to ride the wave of this technological tsunami.

Ground Floor Opportunity: Remember the early days of the internet?

Those who saw the potential of tech giants back then are sitting pretty today.

AI is at a similar inflection point.

We’re not talking about established players – we’re talking about nimble startups with groundbreaking ideas and the potential to become the next Google or Amazon.

This is your chance to get in before the rockets take off!

Disruption is the New Name of the Game: Let’s face it, complacency breeds stagnation.

AI is the ultimate disruptor, and it’s shaking the foundations of traditional industries.

The companies that embrace AI will thrive, while the dinosaurs clinging to outdated methods will be left in the dust.

As an investor, you want to be on the side of the winners, and AI is the winning ticket.

The Talent Pool is Overflowing: The world’s brightest minds are flocking to AI.

From computer scientists to mathematicians, the next generation of innovators is pouring its energy into this field.

This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements.

By investing in AI, you’re essentially backing the future.

The future is powered by artificial intelligence, and the time to invest is NOW.

Don’t be a spectator in this technological revolution.

Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation.

This isn’t just about making money – it’s about being part of the future.

So, buckle up and get ready for the ride of your investment life!

Act Now and Unlock a Potential 10,000% Return: This AI Stock is a Diamond in the Rough (But Our Help is Key!)

The AI revolution is upon us, and savvy investors stand to make a fortune.

But with so many choices, how do you find the hidden gem – the company poised for explosive growth?

That’s where our expertise comes in.

We’ve got the answer, but there’s a twist…

Imagine an AI company so groundbreaking, so far ahead of the curve, that even if its stock price quadrupled today, it would still be considered ridiculously cheap.

That’s the potential you’re looking at. This isn’t just about a decent return – we’re talking about a 10,000% gain over the next decade!

Our research team has identified a hidden gem – an AI company with cutting-edge technology, massive potential, and a current stock price that screams opportunity.

This company boasts the most advanced technology in the AI sector, putting them leagues ahead of competitors.

It’s like having a race car on a go-kart track.

They have a strong possibility of cornering entire markets, becoming the undisputed leader in their field.

Here’s the catch (it’s a good one): To uncover this sleeping giant, you’ll need our exclusive intel.

We want to make sure none of our valued readers miss out on this groundbreaking opportunity!

That’s why we’re slashing the price of our Premium Readership Newsletter by a whopping 70%.

For a ridiculously low price of just $29, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single restaurant meal!

Here’s why this is a deal you can’t afford to pass up:

  • The Name of the Game-Changing AI Stock: Our in-depth report dives deep into our #1 AI stock’s groundbreaking technology and massive growth potential.
  • One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149
  • Ad-Free Browsing: Enjoy a year of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.
  • Lifetime Money-Back Guarantee:  If you’re not absolutely satisfied with our service, we’ll provide a full refund ANYTIME, no questions asked.

 

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

  1. Head over to our website and subscribe to our Premium Readership Newsletter for just $29.
  2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.
  3. Sit back, relax, and know that you’re backed by our ironclad lifetime money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

A New Dawn is Coming to U.S. Stocks

I work for one of the largest independent financial publishers in the world – representing over 1 million people in 148 countries.

We’re independently funding today’s broadcast to address something on the mind of every investor in America right now…

Should I put my money in Artificial Intelligence?

Here to answer that for us… and give away his No. 1 free AI recommendation… is 50-year Wall Street titan, Marc Chaikin.

Marc’s been a trader, stockbroker, and analyst. He was the head of the options department at a major brokerage firm and is a sought-after expert for CNBC, Fox Business, Barron’s, and Yahoo! Finance…

But what Marc’s most known for is his award-winning stock-rating system. Which determines whether a stock could shoot sky-high in the next three to six months… or come crashing down.

That’s why Marc’s work appears in every Bloomberg and Reuters terminal on the planet…

And is still used by hundreds of banks, hedge funds, and brokerages to track the billions of dollars flowing in and out of stocks each day.

He’s used this system to survive nine bear markets… create three new indices for the Nasdaq… and even predict the brutal bear market of 2022, 90 days in advance.

Click to continue reading…